Maria Belen Jimenez-Diaz
Overview
Explore the profile of Maria Belen Jimenez-Diaz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nie Z, Bonnert R, Tsien J, Deng X, Higgs C, El Mazouni F, et al.
J Med Chem
. 2024 Dec;
68(1):590-637.
PMID: 39710971
Malaria remains a serious global health challenge, yet treatment and control programs are threatened by drug resistance. Dihydroorotate dehydrogenase (DHODH) was clinically validated as a target for treatment and prevention...
2.
Lawong A, Gahalawat S, Ray S, Ho N, Han Y, Ward K, et al.
Cell Chem Biol
. 2024 Jul;
31(8):1503-1517.e19.
PMID: 39084225
Malaria remains a global health concern as drug resistance threatens treatment programs. We identified a piperidine carboxamide (SW042) with anti-malarial activity by phenotypic screening. Selection of SW042-resistant Plasmodium falciparum (Pf)...
3.
Kovada V, Withers-Martinez C, Bobrovs R, Ce Rule H, Liepins E, Grinberga S, et al.
J Med Chem
. 2023 Jul;
66(15):10658-10680.
PMID: 37505188
The aspartic protease plasmepsin X (PMX) is essential for the egress of invasive merozoite forms of the parasite. PMX has therefore emerged as a new potential antimalarial target. Building on...
4.
Lowe M, Cardenas A, Valentin J, Zhu Z, Abendroth J, Castro J, et al.
J Med Chem
. 2022 Oct;
65(20):14121-14143.
PMID: 36216349
Plasmepsin X (PMX) is an essential aspartyl protease controlling malaria parasite egress and invasion of erythrocytes, development of functional liver merozoites (prophylactic activity), and blocking transmission to mosquitoes, making it...
5.
de Vries L, Jansen P, Barcelo C, Munro J, Verhoef J, Pasaje C, et al.
Nat Commun
. 2022 Apr;
13(1):2158.
PMID: 35444200
Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase (AcAS) inhibitor to enter preclinical development. Our...
6.
Taft B, Yokokawa F, Kirrane T, Mata A, Huang R, Blaquiere N, et al.
J Med Chem
. 2022 Mar;
65(5):3798-3813.
PMID: 35229610
A series of 5-aryl-2-amino-midazohiaiazole (ITD) derivatives were identified by a phenotype-based high-throughput screening using a blood stage () growth inhibition assay. A lead optimization program focused on improving antiplasmodium potency,...
7.
Murithi J, Pascal C, Bath J, Boulenc X, Gnadig N, Pasaje C, et al.
Sci Transl Med
. 2021 Jul;
13(603).
PMID: 34290058
The emergence and spread of resistance to first-line antimalarials creates an imperative to identify and develop potent preclinical candidates with distinct modes of action. Here, we report the identification of...
8.
Palmer M, Deng X, Watts S, Krilov G, Gerasyuto A, Kokkonda S, et al.
J Med Chem
. 2021 Apr;
64(9):6085-6136.
PMID: 33876936
Dihydroorotate dehydrogenase (DHODH) has been clinically validated as a target for the development of new antimalarials. Experience with clinical candidate triazolopyrimidine DSM265 () suggested that DHODH inhibitors have great potential...
9.
Peric M, Pesic D, Alihodzic S, Fajdetic A, Herreros E, Gamo F, et al.
Br J Pharmacol
. 2020 Oct;
178(2):363-377.
PMID: 33085774
Background And Purpose: Efficacy of current antimalarial treatments is declining as a result of increasing antimalarial drug resistance, so new and potent antimalarial drugs are urgently needed. Azithromycin, an azalide...
10.
Kokkonda S, Deng X, White K, El Mazouni F, White J, Shackleford D, et al.
J Med Chem
. 2020 Apr;
63(9):4929-4956.
PMID: 32248693
Malaria puts at risk nearly half the world's population and causes high mortality in sub-Saharan Africa, while drug resistance threatens current therapies. The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) is...